- Market Capitalization, $K 6,312,177
- Shares Outstanding, K 65,074
- Annual Sales, $ 63,630 K
- Annual Income, $ -766,800 K
- 60-Month Beta 1.01
- Price/Sales 97.15
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+18.05 (+22.80%)since 05/21/21
| || |
+24.99 (+34.61%)since 03/22/21
| || |
+23.51 (+31.90%)since 06/22/20
/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of , Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board")....
CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer,...
, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 19 abstracts, including one late-breaking presentation and two oral presentations, will be presented...
The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.
, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC® ODT (rimegepant 75 mg) for the preventive...
ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021
, /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. Nurtec ODT's...
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
|Biohaven Pharmaceutical Holding Ltd|
|Bioshares Biotech Products|
|Principal Healthcare Innovators Index|
|S&P Biotech SPDR|
|Nasdaq Biotechnology Ishares ETF|
|Russell 2000 Growth Ishares ETF|
|3rd Resistance Point||102.78|
|2nd Resistance Point||100.93|
|1st Resistance Point||99.07|
|1st Support Level||95.36|
|2nd Support Level||93.51|
|3rd Support Level||91.65|